Diabetes Drug Lowers CV Events, but at Serious Cost: Amputation Risk

A new study demonstrates that a relatively new and popular diabetes drug, Invokana (canagliflozin), also has cardiovascular benefits, such as reducing the risk of heart attacks, but at a serious cost – an increased risk of leg and foot amputation.

Conducted by Invokana’s manufacturer, Janssen Pharmaceutical, results showed that patients on Invokana saw the risk of cardiovascular events decline by 14% compared to those on placebo. The drug also lowered the risk of kidney decline by 40%. Results were presented at both the American Diabetes Association annual meeting and in the New England Journal of Medicine.

But the research also showed that patients taking Invokana had nearly twice the risk of amputation – primarily in the foot and toes – compared with those on placebo. The FDA was already aware of this and mandated a “black box” warning – the most stringent the agency can require – on the drug’s labeling about the amputation risk last month.

Invokana is part of the newest class of diabetes medications known as SGLT-2 inhibitors. A trial published in 2015 showed that Jardiance (empagliflozin) also had cardiovascular benefits. However, unlike Jardiance, Invokana did not demonstrate a reduction in cardiovascular death in the newest study.


Did you find this article helpful?


Latest News

Breaking News – EpiPen Malfunction

Breaking News – EpiPen Malfunction

Just released from the FDA – Pfizer has informed the FDA that they are aware of several continuing problems that people are having using the EpiPen (epinephrine) and EpiPen Jr (epinephrine) auto-injectors and generic versions. Some of the problems are from user error and some from EpiPen malfunction. Here are…

ACE Inhibitors in the Time of Coronavirus

ACE Inhibitors in the Time of Coronavirus

Are you worried about ACE inhibitors and coronavirus? You may be hearing that one of the entry methods for the coronavirus in humans is by attaching to the ACE-2 enzyme. This has raised alarms among those with heart disease who use ACE inhibitors (with names ending in -pril, such as…

  • Advertisement